Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 3/20 | 0.73 |
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.66 |
| ▸ | RAB9A | P51151 | 3/20 | 0.65 |
| ▸ | NPC1 | O15118 | 2/20 | 0.65 |
| ▸ | CASP3 | P42574 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.65 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.65 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.63 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.62 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.62 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.62 |
| ▸ | KCNE1 | P15382 | 2/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14445617 | 0.88 | MAPT (0.70) | PTGS1LMNAP2RX1RAB9AMEN1 | |
| SCHEMBL8363755 | 0.85 | MEN1 (0.77) | PTGS1LMNAP2RX1RAB9ASMN1; SMN2 | |
| SCHEMBL5131380 | 0.85 | RHOC (0.80) | PTGS1LMNAP2RX1RAB9ANPC1 | |
| SCHEMBL3454009 | 0.85 | PTGS1 (1.00) | PTGS1LMNAP2RX1RAB9ANPC1 | |
| SCHEMBL14445616 | 0.84 | CSF1R (0.61) | PTGS1LMNAP2RX1RAB9AMEN1 | |
| SCHEMBL28668959 | 0.83 | LMNA (0.83) | PTGS1LMNAP2RX1RAB9ANPC1 | |
| SCHEMBL30739967 | 0.83 | LMNA (0.78) | PTGS1LMNAP2RX1RAB9ANPC1 | |
| SCHEMBL23844170 | 0.83 | NPC1 (0.76) | LMNARAB9ANPC1CASP3SMN1; SMN2 | |
| SCHEMBL4517587 | 0.83 | LMNA (1.00) | PTGS1LMNAP2RX1RAB9ANPC1 | |
| SCHEMBL30739929 | 0.83 | LMNA (1.00) | PTGS1LMNAP2RX1RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9321766-B1 | Kinase inhibitors | ALLERGAN, INC. (US) | 2016-04-26 | — | — | US | disclosed |
| US-20160096832-A1 | KINASE INHIBITORS | ALLERGAN, INC. | 2016-04-07 | — | — | US | disclosed |
| US-20070161645-A1 | Thiazole inhibitors targeting resistant kinase mutations | TARGEGEN, INC. (US) | 2007-07-12 | — | — | US | disclosed |
| US-20070149508-A1 | Six membered heteroaromatic inhibitors targeting resistant kinase mutations | TARGEGEN, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| US-20070149508-A1 | Six membered heteroaromatic inhibitors targeting resistant kinase mutations | TARGEGEN, INC. (US) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161645-A1 | Thiazole inhibitors targeting resistant kinase mutations | JAK2, ABL1, FLT3 | PTGS1 2024/4885LMNA 2025/4885P2RX1 4186/4885 |
| US-20160096832-A1 | KINASE INHIBITORS | ABL1, LCK, ERBB2 | PTGS1 1317/4885LMNA 4604/4885P2RX1 2952/4885 |
| US-20070149508-A1 | Six membered heteroaromatic inhibitors targeting resistant kinase mutations | ABL1, KDR, BCR | PTGS1 2118/4885LMNA 1837/4885P2RX1 4518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.